News

Abbott has signed a partnership with Velcera to market the first canine pain management product, delivered in a transmucosal mist form. Currently in clinical trials, the product combines

PCAS has declared that it is planing to set up a Kilolab in California, US, aimed at small scale synthesis market. By establishing early relationships, the company expects

IsoRay has received clearance from the FDA for its Premarket Notification, 510(k) for Proxcelan Cesium-131 Brachytherapy Seeds. It would enable the company to preload Cesium-131 into flexible braided

Oculus Innovative Sciences has commercialized its Microcyn Skin and Wound Cleanser with preservatives, in both professional and over-the-counter formulations. Reportedly, the professional product is indicated for use by

Genmab has reported an increase in revenues of $66m for the first half of 2009, compared to $53m for the same period an year ago. The company also

Covance has closed its transaction with Merck to provide an array of genomics analysis services under a five-year $145m contract, and to acquire Merck’s Seattle-based Gene Expression Laboratory.

DURECT has signed a development and license agreement with Orient Pharma. Under the terms of the agreement, DURECT has granted development and commercialization rights to Orient Pharma, in

SyntheMed has received approval from the Ministry of Health of the Russian Federation for use of REPEL-CV in all patients who undergo open heart surgery. Reportedly, REPEL-CV is

4SC has reported the dosing of the first patient in its phase II trial with 4SC-201 (resminostat), a pan-histone deacetylase (HDAC) inhibitor, as a new potential treatment option